Clinical—Liver, Pancreas, and Biliary TractHuman Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
Section snippets
Patient Selection and Consent
Patients entering RTOG 9704 gave consent for use of formalin-fixed tissue for future planned translational research as part of the formal informed consent process. The RTOG tissue bank received tumor blocks from a total of 229 of the 538 patients who had undergone surgical resection and were entered in the RTOG 9704 prospective adjuvant treatment trial. Tissue microarrays (TMAs) were constructed from these blocks. Clinicopathologic factors were obtained as part of the patients' enrollment in
Patient Population
The study opened July 20, 1998, and closed on July 26, 2002, with a total of 538 patients, and the final results have been published.19 Eighty-seven percent and 86% of patients assigned to the 5-FU group completed chemotherapy and radiotherapy, respectively, as planned. Ninety percent and 88% of patients assigned to the gemcitabine group completed chemotherapy and radiotherapy, respectively, as planned. Of the 268 patients entered in the gemcitabine arm, 91 were eligible and had analyzable
Discussion
This current study studied hENT1 in a phase III adjuvant therapy trial in early stage pancreas cancer. Patients were randomized to receive gemcitabine or 5-FU as part of their systemic therapy. Although slightly less than 50% of the patients entered into the trial had tissue available for hENT1 analysis, the missing data are not expected to bias our results because there were no significant imbalances between patient and tumor baseline characteristics (including tumor and nodal stage) in the
References (35)
- et al.
Nucleoside transporters: molecular biology and implications for therapeutic development
Mol Med Today
(1999) - et al.
Molecular identification and characterization of novel human and mouse concentrative Na+-nucleoside cotransporter proteins (hCNT3 and mCNT3) broadly selective for purine and pyrimidine nucleosides (system cib)
J Biol Chem
(2001) - et al.
2′,2′-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines
Biochem Pharmacol
(1993) - et al.
Thirty novel genetic variations in the SLC29A1 gene encoding human equilibrative nucleoside transporter 1 (hENT1)
Drug Metab Pharmacokinet
(2006) - et al.
A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer
Ann Oncol
(2005) - et al.
Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial
J Clin Oncol
(1997) - et al.
Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines
Cancer Res
(1998) - et al.
Gemcitabine transport in xenopus oocytes expressing recombinant plasma membrane mammalian nucleoside transporters
J Natl Cancer Inst
(1999) - et al.
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2′,2′-difluorodeoxycytidine-induced cytotoxicity
Clin Cancer Res
(2003) - et al.
Nucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapy
Oncogene
(2003)
Induction of apoptosis by gemcitabine
Semin Oncol
Gemcitabine: preclinical pharmacology and mechanisms of action
Semin Oncol
Modulation of deoxycytidylate deaminase in intact human leukemia cellsAction of 2′,2′-difluorodeoxycytidine
Biochem Pharmacol
Gemcitabine: a modulator of intracellular nucleotide and deoxynucleotide metabolism
Semin Oncol
Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells
Oncol Rep
Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells
Br J Cancer
Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer
Cancer Sci
Cited by (381)
Role of exosomes in transferring chemoresistance through modulation of cancer glycolytic cell metabolism
2023, Cytokine and Growth Factor ReviewsPrecision Medicine for Pancreas Cancer Treatment: A Multidisciplinary Challenge or Opportunity?
2023, Clinical Gastroenterology and HepatologyMolecular biomarkers in pancreatic ductal adenocarcinoma
2023, Biomarkers in Cancer Detection and Monitoring of Therapeutics: Diagnostic and Therapeutic Applications: Volume 2Personalized medicine and new therapeutic approach in the treatment of pancreatic cancer
2023, Recent Advances in Nanocarriers for Pancreatic Cancer Therapy
The authors disclose the following: Funded by a RTOG Seed Grant and a National Institutes of Health K12 Career Development Award in Clinical Pharmacology (J.J.F.) and by an American Society of Therapeutic Radiology and Oncology Junior Faculty Award (H.E.).